Cipher Pharmaceuticals (TSE:CPH) Stock Price Crosses Above 50 Day Moving Average of $8.80

Cipher Pharmaceuticals Inc. (TSE:CPHGet Free Report) (NASDAQ:CPHR) passed above its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of C$8.80 and traded as high as C$8.99. Cipher Pharmaceuticals shares last traded at C$8.88, with a volume of 12,400 shares.

Analyst Ratings Changes

A number of equities analysts have weighed in on CPH shares. Stifel Nicolaus cut shares of Cipher Pharmaceuticals from a “buy” rating to a “hold” rating and upped their price objective for the stock from C$8.00 to C$9.50 in a research report on Monday, May 13th. Citigroup upped their price target on shares of Cipher Pharmaceuticals from C$4.75 to C$8.00 and gave the stock a “buy” rating in a research report on Wednesday, February 14th.

Check Out Our Latest Stock Analysis on CPH

Cipher Pharmaceuticals Stock Performance

The company has a quick ratio of 2.67, a current ratio of 7.96 and a debt-to-equity ratio of 0.38. The firm has a 50-day moving average price of C$8.80 and a two-hundred day moving average price of C$7.25. The firm has a market cap of C$211.20 million, a PE ratio of 7.28 and a beta of 1.05.

Cipher Pharmaceuticals (TSE:CPHGet Free Report) (NASDAQ:CPHR) last announced its quarterly earnings data on Thursday, May 9th. The company reported C$0.27 earnings per share for the quarter, beating analysts’ consensus estimates of C$0.14 by C$0.13. Cipher Pharmaceuticals had a return on equity of 29.70% and a net margin of 102.43%. The company had revenue of C$7.91 million for the quarter, compared to analyst estimates of C$7.04 million. Research analysts forecast that Cipher Pharmaceuticals Inc. will post 0.74 EPS for the current fiscal year.

About Cipher Pharmaceuticals

(Get Free Report)

Cipher Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome.

See Also

Receive News & Ratings for Cipher Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cipher Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.